back

Vorapaxar

Subject:

  • Active Substance: Vorapaxar
  • Name: ZONTIVITY
  • Therapeutic area: Reduction of thrombotic cardiovascular events
  • Pharmaceutical company: Merck & Company Inc.

 

Time table:

  • Publication of final assessment: 17.06.2015

 

Assessment information:

  • Title: Vorapaxar for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infection (MI)
  • Author/Co-Author: HAS (France), MoH Slovak Republic (Slovakia)
  • Dedicated Reviewers: AOTMiT (Poland), SNHTA (Switzerland), AQUAS (Spain), HVB (Austria), SMC (Scotland), ZIN (Netherlands)

G-BA assessment not available
Reason: The marketing authorisation for Vorapaxar has been withdrawn at the request of the marketing authorisation holder.